Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:INMD NASDAQ:TMDX NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$43.00$39.33$9.22▼$45.83$2.29B1.12905,620 shs1.55 million shsINMDInMode$13.45$13.92$12.72▼$16.74$852.19M1.94795,809 shs448,432 shsTMDXTransMedics Group$72.91$86.20$60.10▼$156.00$2.52B1.921.18 million shs658,538 shsWRBYWarby Parker$26.32-0.5%$24.31$14.96▼$31.00$2.82B1.963.01 million shs2.22 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%+0.47%+4.90%+30.94%+341.03%INMDInMode0.00%-0.66%-3.24%+0.15%+0.67%TMDXTransMedics Group0.00%+5.01%+15.36%-41.53%-48.97%WRBYWarby Parker0.00%+16.03%-8.42%+14.96%+19.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$43.00$39.33$9.22▼$45.83$2.29B1.12905,620 shs1.55 million shsINMDInMode$13.45$13.92$12.72▼$16.74$852.19M1.94795,809 shs448,432 shsTMDXTransMedics Group$72.91$86.20$60.10▼$156.00$2.52B1.921.18 million shs658,538 shsWRBYWarby Parker$26.32-0.5%$24.31$14.96▼$31.00$2.82B1.963.01 million shs2.22 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%+0.47%+4.90%+30.94%+341.03%INMDInMode0.00%-0.66%-3.24%+0.15%+0.67%TMDXTransMedics Group0.00%+5.01%+15.36%-41.53%-48.97%WRBYWarby Parker0.00%+16.03%-8.42%+14.96%+19.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 2.73Moderate Buy$46.508.14% UpsideINMDInMode 2.00Hold$16.0018.96% UpsideTMDXTransMedics Group 2.46Hold$134.0083.79% UpsideWRBYWarby Parker 2.64Moderate Buy$29.5012.07% UpsideCurrent Analyst Ratings BreakdownLatest INMD, WRBY, TMDX, and AXGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026TMDXTransMedics Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/29/2026AXGNAxoGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026AXGNAxoGen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/26/2026TMDXTransMedics Group UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/26/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$85.00 ➝ $75.005/22/2026WRBYWarby Parker CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/19/2026WRBYWarby Parker Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/11/2026WRBYWarby Parker Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C-)5/8/2026WRBYWarby Parker UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$25.00 ➝ $27.005/8/2026WRBYWarby Parker Telsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$32.00 ➝ $33.005/7/2026INMDInMode BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$21.00 ➝ $19.00(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$225.21M10.15N/AN/A$2.79 per share15.41INMDInMode$370.49M2.30$1.49 per share9.02$10.78 per share1.25TMDXTransMedics Group$605.49M4.16$3.93 per share18.57$13.79 per share5.29WRBYWarby Parker$871.91M3.23$0.63 per share42.06$3.48 per share7.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$15.70M-$0.64N/A159.26N/A-13.21%-9.63%-6.26%8/4/2026 (Estimated)INMDInMode$93.83M$1.369.89N/AN/A23.27%13.47%11.95%7/23/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4016.5720.20N/A27.04%22.38%8.46%7/30/2026 (Estimated)WRBYWarby Parker$1.64M$0.021,316.8665.81N/A0.15%2.30%1.18%8/6/2026 (Estimated)Latest INMD, WRBY, TMDX, and AXGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026WRBYWarby Parker$0.11$0.03-$0.08$0.03$239.44 million$242.45 million5/6/2026Q1 2026INMDInMode$0.2978$0.25-$0.0478$0.18$79.84 million$82.02 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million4/28/2026Q1 2026AXGNAxoGen$0.12$0.07-$0.05-$0.38$57.85 million$61.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/AINMDInModeN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.087.105.33INMDInModeN/A8.807.88TMDXTransMedics Group1.706.746.19WRBYWarby ParkerN/A2.332.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%INMDInMode68.04%TMDXTransMedics Group99.67%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.44%INMDInMode6.92%TMDXTransMedics Group6.90%WRBYWarby Parker16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45053.18 million51.88 millionOptionableINMDInMode48063.36 million58.98 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableWRBYWarby Parker4,036107.09 million89.10 millionOptionableINMD, WRBY, TMDX, and AXGN HeadlinesRecent News About These CompaniesA Warby Parker Director Sold 10,000 Company Shares. Here's a Deeper Look at the Transaction.June 14 at 7:13 PM | fool.comNiles Investment Management LLC Purchases Shares of 63,169 Warby Parker Inc. $WRBYJune 14 at 7:01 AM | marketbeat.comInsider Selling: Warby Parker (NYSE:WRBY) Director Sells 10,000 Shares of StockJune 13 at 7:19 AM | insidertrades.comWarby Parker Stockholders Back Directors and Executive PayJune 12 at 7:31 PM | tipranks.comRational Advisors Inc. Purchases New Position in Warby Parker Inc. $WRBYJune 3, 2026 | marketbeat.comWarby Parker Announces Participation in Upcoming 2026 Baird Global Consumer, Technology & Services ConferenceMay 28, 2026 | businesswire.comKing Luther Capital Management Corp Has $9.22 Million Position in Warby Parker Inc. $WRBYMay 28, 2026 | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 27, 2026 | marketbeat.comFuture of 'A-Eye': Warby Parker co-CEOs on the company's new AI glassesMay 26, 2026 | youtube.comYWellington Shields Capital Management LLC Buys New Shares in Warby Parker Inc. $WRBYMay 26, 2026 | marketbeat.comSimplify Asset Management Inc. Buys New Position in Warby Parker Inc. $WRBYMay 25, 2026 | marketbeat.comThe Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind...May 24, 2026 | marketbeat.comNeil Harris Blumenthal Sells 63,040 Shares of Warby Parker (NYSE:WRBY) StockMay 22, 2026 | insidertrades.com47,191 Shares in Warby Parker Inc. $WRBY Purchased by Fortis Group Advisors LLCMay 22, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) CEO Sells $1,893,091.20 in StockMay 21, 2026 | marketbeat.comWarby Parker Offers Glimpse of Google-Powered Smart GlassesMay 20, 2026 | pymnts.comWarby Parker slides as investors compare its smart glasses to the Meta Ray-Ban lineMay 20, 2026 | msn.comWarby Parker Stock Slumps 11% as Questions Cloud Its Google Gemini AI Eyewear RevealMay 19, 2026 | barrons.comWarby Parker (NYSE:WRBY) Trading Down 6.6% - Here's WhyMay 19, 2026 | marketbeat.comGoogle and Samsung's Warby Parker and Gentle Monster Glasses Are Coming This FallMay 19, 2026 | cnet.comWarby Parker Unveils First Intelligent Eyewear DesignMay 19, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Why Applied Optoelectronics Stock May Be Near a Turning PointBy Thomas Hughes | May 18, 2026INMD, WRBY, TMDX, and AXGN Company DescriptionsAxoGen NASDAQ:AXGN$43.00 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$42.36 -0.65 (-1.50%) As of 06/12/2026 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.InMode NASDAQ:INMD$13.45 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$13.42 -0.04 (-0.26%) As of 06/12/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.TransMedics Group NASDAQ:TMDX$72.91 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$72.97 +0.06 (+0.09%) As of 06/12/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Warby Parker NYSE:WRBY$26.32 -0.14 (-0.51%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$26.42 +0.10 (+0.38%) As of 06/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
